DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ICLUSIG

« Back to Dashboard

Clinical Trials for Iclusig

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00660920	Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies	Active, not recruiting	Ariad Pharmaceuticals	Phase 1	The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule (QD) in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.
NCT01207440	Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)	Active, not recruiting	Ariad Pharmaceuticals	Phase 2	The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation.
NCT01620216	Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia	Recruiting	National Cancer Institute (NCI)	Phase 2	This phase II trial studies how well targeted therapy works in treating patients with acute lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of improvement or does not respond to treatment. Testing patients' blood or bone marrow to find out if their type of cancer may be sensitive to a specific drug may help doctors choose more effective treatments. Dasatinib, nilotinib, sunitinib malate, sorafenib tosylate, and ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving targeted therapy based on cancer type may be an effective treatment for acute lymphoblastic leukemia or acute myelogenous leukemia.
NCT01620216	Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia	Recruiting	OHSU Knight Cancer Institute	Phase 2	This phase II trial studies how well targeted therapy works in treating patients with acute lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of improvement or does not respond to treatment. Testing patients' blood or bone marrow to find out if their type of cancer may be sensitive to a specific drug may help doctors choose more effective treatments. Dasatinib, nilotinib, sunitinib malate, sorafenib tosylate, and ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving targeted therapy based on cancer type may be an effective treatment for acute lymphoblastic leukemia or acute myelogenous leukemia.

Clinical Trial Conditions for Iclusig

Condition Name

Condition Name for Iclusig
Intervention	Trials
Acute Lymphoblastic Leukemia	2
Leukemia	2
Acute Lymphoid Leukemia	1
Stage IV Non-small Cell Lung Cancer	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Iclusig
Intervention	Trials
Leukemia	11
Leukemia, Myeloid	7
Precursor Cell Lymphoblastic Leukemia-Lymphoma	6
Leukemia, Lymphoid	6

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Iclusig

Trials by Country

Trials by Country for Iclusig
Location	Trials
United States	52
Japan	7
Australia	6
France	6
Canada	6

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Iclusig
Location	Trials
Texas	8
Oregon	6
Michigan	4
California	3
Utah	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Iclusig

Clinical Trial Phase

Clinical Trial Phase for Iclusig
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	9
Phase 1/Phase 2	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Iclusig
Clinical Trial Phase	Trials
Recruiting	9
Not yet recruiting	3
Active, not recruiting	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Iclusig

Sponsor Name

Sponsor Name for Iclusig
Sponsor	Trials
Ariad Pharmaceuticals	9
M.D. Anderson Cancer Center	4
National Cancer Institute (NCI)	2

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Iclusig
Sponsor	Trials
Industry	12
Other	9
NIH	2

Export unavailable in trial.
Subscribe for complete access.